2021
A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus
Wunder EA, Adhikarla H, Hamond C, Bonner K, Liang L, Rodrigues CB, Bisht V, Nally JE, Alt DP, Reis MG, Diggle PJ, Felgner PL, Ko A. A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus. ELife 2021, 10: e64166. PMID: 33496263, PMCID: PMC7837694, DOI: 10.7554/elife.64166.Peer-Reviewed Original ResearchConceptsCross-protective immunityPathogenic Leptospira speciesTerms of morbidityLeptospira speciesTransient bacteremiaSingle doseAntibody responseImmune responseApplicable vaccinesVaccine candidatesAnimal modelsEffective preventionAttenuated mutantsZoonotic diseaseLeptospira genusPotential correlatesDisease transmissionDiseaseLeptospirosisImmunityBacteremiaMorbidityImmunizationVaccineRelevant proteins
2016
Cathelicidin Insufficiency in Patients with Fatal Leptospirosis
Lindow JC, Wunder EA, Popper SJ, Min JN, Mannam P, Srivastava A, Yao Y, Hacker KP, Raddassi K, Lee PJ, Montgomery RR, Shaw AC, Hagan JE, Araújo GC, Nery N, Relman DA, Kim CC, Reis MG, Ko AI. Cathelicidin Insufficiency in Patients with Fatal Leptospirosis. PLOS Pathogens 2016, 12: e1005943. PMID: 27812211, PMCID: PMC5094754, DOI: 10.1371/journal.ppat.1005943.Peer-Reviewed Original ResearchConceptsHost immune responseHigh bacterial loadBacterial loadAcute leptospirosisCase fatalityFatal casesDisease progressionImmune responseHigher systemic bacterial loadsValuable new therapeutic approachPro-inflammatory cytokine receptorsAdaptive immune signaturesSystemic bacterial loadsIndependent risk factorTime of hospitalizationDuration of illnessHigh case fatalityPoor clinical outcomeNew therapeutic approachesBlood transcriptional profilingLimited study sizeFatal leptospirosisLethal leptospirosisRANTES levelsSerum cathelicidin